Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FBRX Forte Biosciences	$10.55 -7.9%	$10.35	$4.11 ▼ $28.68	$75.41M	2.97	173,621 shs	96,634 shs
KALA KALA BIO	$5.85 -15.2%	$4.28	$2.92 ▼ $11.20	$44.52M	-1.88	49,005 shs	154,051 shs
SPPI Spectrum Pharmaceuticals	$1.03	$1.01	$0.32 ▼ $1.57	$211.41M	2.15	1.93 million shs	N/A
TORC resTORbio	$0.75 +1.3%	$12.16	$0.86 ▼ $10.50	$27.32M	2.43	1.15 million shs	481,609 shs
VKTX Viking Therapeutics	$31.11 -0.6%	$27.61	$18.92 ▼ $81.73	$3.51B	0.62	4.06 million shs	2.83 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FBRX Forte Biosciences	-7.86%	-23.61%	-16.27%	+100.95%	+51,615.69%
KALA KALA BIO	-15.22%	+10.59%	+33.56%	+73.59%	-23.03%
SPPI Spectrum Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
TORC resTORbio	+3.76%	+21.88%	-9.78%	+65.47%	-41.75%
VKTX Viking Therapeutics	-0.58%	+10.48%	+7.46%	+40.01%	-46.35%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FBRX Forte Biosciences	3.5262 of 5 stars	3.5	5.0	0.0	0.0	3.5	1.7	0.6
KALA KALA BIO	3.9717 of 5 stars	3.5	2.0	0.0	4.4	2.4	0.8	0.6
SPPI Spectrum Pharmaceuticals	0.4393 of 5 stars	0.0	0.0	0.0	4.7	0.6	0.0	0.6
TORC resTORbio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VKTX Viking Therapeutics	4.5031 of 5 stars	3.5	5.0	0.0	4.7	2.2	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FBRX Forte Biosciences	3.00	Buy	$61.00	478.20% Upside
KALA KALA BIO	3.00	Buy	$13.00	122.22% Upside
SPPI Spectrum Pharmaceuticals	0.00	N/A	N/A	N/A
TORC resTORbio	0.00	N/A	N/A	N/A
VKTX Viking Therapeutics	3.00	Buy	$87.15	180.15% Upside

Current Analyst Ratings Breakdown

Latest TORC, FBRX, VKTX, KALA, and SPPI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/11/2025	KALA KALA BIO	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/25/2025	VKTX Viking Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$102.00
6/24/2025	FBRX Forte Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$61.00
6/2/2025	KALA KALA BIO	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$15.00
5/23/2025	KALA KALA BIO	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $12.00
4/29/2025	VKTX Viking Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/28/2025	VKTX Viking Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$104.00
4/28/2025	VKTX Viking Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$95.00 ➝ $75.00
4/24/2025	VKTX Viking Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$105.00 ➝ $102.00
4/24/2025	VKTX Viking Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$102.00 ➝ $102.00
4/17/2025	VKTX Viking Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$102.00 ➝ $102.00

(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	$8.21 per share	N/A
KALA KALA BIO	$3.89M	9.70	N/A	N/A	$2.02 per share	2.90
SPPI Spectrum Pharmaceuticals	$10.11M	20.91	N/A	N/A	$0.15 per share	6.87
TORC resTORbio	N/A	N/A	N/A	N/A	$2.24 per share	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	$7.90 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FBRX Forte Biosciences	-$35.48M	-$16.29	N/A	N/A	N/A	N/A	-149.15%	-114.25%	8/13/2025 (Estimated)
KALA KALA BIO	-$38.51M	-$8.24	N/A	N/A	N/A	N/A	-369.29%	-64.99%	8/5/2025 (Estimated)
SPPI Spectrum Pharmaceuticals	-$75.40M	-$0.36	N/A	14.71	N/A	N/A	-218.44%	-66.16%	N/A
TORC resTORbio	-$82.74M	-$2.41	N/A	N/A	N/A	N/A	-78.12%	-71.63%	N/A
VKTX Viking Therapeutics	-$109.96M	-$1.15	N/A	N/A	N/A	N/A	-14.41%	-14.02%	7/23/2025 (Estimated)

Latest TORC, FBRX, VKTX, KALA, and SPPI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	KALA KALA BIO	-$1.82	N/A	N/A	N/A	N/A	N/A
7/23/2025	Q2 2025	VKTX Viking Therapeutics	-$0.44	N/A	N/A	N/A	N/A	N/A
5/15/2025	Q1 2025	FBRX Forte Biosciences	-$0.89	-$1.37	-$0.48	-$1.37	N/A	N/A
4/23/2025	Q1 2025	VKTX Viking Therapeutics	-$0.31	-$0.41	-$0.10	-$0.41	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FBRX Forte Biosciences	N/A	N/A	N/A	N/A	N/A
KALA KALA BIO	N/A	N/A	N/A	N/A	N/A
SPPI Spectrum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TORC resTORbio	N/A	N/A	N/A	N/A	N/A
VKTX Viking Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FBRX Forte Biosciences	N/A	5.22	5.22
KALA KALA BIO	3.19	1.99	1.99
SPPI Spectrum Pharmaceuticals	N/A	2.71	2.38
TORC resTORbio	N/A	20.69	20.69
VKTX Viking Therapeutics	N/A	44.25	44.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FBRX Forte Biosciences	77.63%
KALA KALA BIO	24.61%
SPPI Spectrum Pharmaceuticals	21.67%
TORC resTORbio	46.19%
VKTX Viking Therapeutics	76.03%

Insider Ownership

Company	Insider Ownership
FBRX Forte Biosciences	5.90%
KALA KALA BIO	8.32%
SPPI Spectrum Pharmaceuticals	2.70%
TORC resTORbio	11.80%
VKTX Viking Therapeutics	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FBRX Forte Biosciences	5	6.58 million	6.20 million	Optionable
KALA KALA BIO	30	6.45 million	5.92 million	Not Optionable
SPPI Spectrum Pharmaceuticals	86	205.25 million	199.70 million	Optionable
TORC resTORbio	N/A	36.45 million	N/A	Not Optionable
VKTX Viking Therapeutics	20	112.31 million	107.71 million	Optionable

TORC, FBRX, VKTX, KALA, and SPPI Headlines

Recent News About These Companies

Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Purchased by Caas Capital Management LP

July 11 at 8:12 AM | marketbeat.com

Banque Pictet & Cie SA Takes Position in Viking Therapeutics, Inc. (NASDAQ:VKTX)

July 11 at 5:39 AM | marketbeat.com

Viking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts

July 10 at 6:46 PM | zacks.com

U.S. Capital Wealth Advisors LLC Sells 8,423 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

July 10 at 5:26 AM | marketbeat.com

Viking Therapeutics (VKTX) Soars 9.7% on Looming Weight Loss Drug Trial Results

July 9 at 4:17 PM | insidermonkey.com

Financial Counselors Inc. Acquires 16,823 Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX)

July 9 at 5:41 AM | marketbeat.com

Viking Therapeutics (NASDAQ:VKTX) Trading Up 8.1% - Still a Buy?

July 8, 2025 | marketbeat.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Bought by Cambridge Investment Research Advisors Inc.

July 8, 2025 | marketbeat.com

Better Growth Buy: Eli Lilly vs. Viking Therapeutics

July 7, 2025 | fool.com

August 22nd Options Now Available For Viking Therapeutics (VKTX)

July 5, 2025 | nasdaq.com

Insider Selling: Viking Therapeutics, Inc. (NASDAQ:VKTX) CFO Sells 4,266 Shares of Stock

July 4, 2025 | insidertrades.com

Why I Think Viking Therapeutics Is an Asymmetric Growth Opportunity

July 4, 2025 | fool.com

Viking Therapeutics, Inc. (VKTX) Rises Higher Than Market: Key Facts

July 3, 2025 | zacks.com

Insider Selling: Viking Therapeutics, Inc. (NASDAQ:VKTX) CFO Sells 4,266 Shares of Stock

July 3, 2025 | marketbeat.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) COO Sells $118,466.82 in Stock

July 3, 2025 | marketbeat.com

Viking Therapeutics, Inc. (NASDAQ:VKTX) CEO Sells 26,889 Shares

July 3, 2025 | marketbeat.com

VKTX - Viking Therapeutics Inc Sustainability - Morningstar

July 3, 2025 | morningstar.comM

H.C. Wainwright Keeps Their Buy Rating on Viking Therapeutics (VKTX)

July 2, 2025 | theglobeandmail.com

Viking Therapeutics (NASDAQ:VKTX) Shares Up 7.7% - Here's What Happened

July 2, 2025 | marketbeat.com

Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic?

July 2, 2025 | zacks.com

Got $200? 2 Biotech Stocks to Buy and Hold Forever

July 1, 2025 | fool.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking
By Chris Markoch | June 29, 2025
View 3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking

TORC, FBRX, VKTX, KALA, and SPPI Company Descriptions

Forte Biosciences NASDAQ:FBRX

$10.55 -0.90 (-7.86%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$10.68 +0.13 (+1.18%)

As of 07/11/2025 04:26 PM Eastern

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.

KALA BIO NASDAQ:KALA

$5.85 -1.05 (-15.22%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$5.98 +0.14 (+2.31%)

As of 07/11/2025 06:55 PM Eastern

KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

Spectrum Pharmaceuticals NASDAQ:SPPI

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.

resTORbio NASDAQ:TORC

Adicet Bio, Inc. is a biotechnology company which engages in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.

Viking Therapeutics NASDAQ:VKTX

$31.11 -0.18 (-0.58%)

Closing price 07/11/2025 04:00 PM Eastern

Extended Trading

$31.14 +0.03 (+0.10%)

As of 07/11/2025 07:59 PM Eastern

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time